Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 110

1.

PDE4 inhibitors induce emesis in ferrets via a noradrenergic pathway.

Robichaud A, Savoie C, Stamatiou PB, Tattersall FD, Chan CC.

Neuropharmacology. 2001;40(2):262-9.

PMID:
11114405
2.

Assessing the emetic potential of PDE4 inhibitors in rats.

Robichaud A, Savoie C, Stamatiou PB, Lachance N, Jolicoeur P, Rasori R, Chan CC.

Br J Pharmacol. 2002 Jan;135(1):113-8.

3.

Deletion of phosphodiesterase 4D in mice shortens alpha(2)-adrenoceptor-mediated anesthesia, a behavioral correlate of emesis.

Robichaud A, Stamatiou PB, Jin SL, Lachance N, MacDonald D, Laliberté F, Liu S, Huang Z, Conti M, Chan CC.

J Clin Invest. 2002 Oct;110(7):1045-52.

4.

The identification of a novel phosphodiesterase 4 inhibitor, 1-ethyl-5-{5-[(4-methyl-1-piperazinyl)methyl]-1,3,4-oxadiazol-2-yl}-N-(tetrahydro-2H-pyran-4-yl)-1H-pyrazolo[3,4-b]pyridin-4-amine (EPPA-1), with improved therapeutic index using pica feeding in rats as a measure of emetogenicity.

Davis TG, Peterson JJ, Kou JP, Capper-Spudich EA, Ball D, Nials AT, Wiseman J, Solanke YE, Lucas FS, Williamson RA, Ferrari L, Wren P, Knowles RG, Barnette MS, Podolin PL.

J Pharmacol Exp Ther. 2009 Sep;330(3):922-31. doi: 10.1124/jpet.109.152454. Epub 2009 Jun 4.

5.

Luteolin, a non-selective competitive inhibitor of phosphodiesterases 1-5, displaced [3H]-rolipram from high-affinity rolipram binding sites and reversed xylazine/ketamine-induced anesthesia.

Yu MC, Chen JH, Lai CY, Han CY, Ko WC.

Eur J Pharmacol. 2010 Feb 10;627(1-3):269-75. doi: 10.1016/j.ejphar.2009.10.031. Epub 2009 Oct 22.

PMID:
19853596
6.

Alpha adrenoceptor subtypes involved in the emetic action in dogs.

Hikasa Y, Ogasawara S, Takase K.

J Pharmacol Exp Ther. 1992 May;261(2):746-54.

PMID:
1349647
7.

Emesis induced by inhibitors of type IV cyclic nucleotide phosphodiesterase (PDE IV) in the ferret.

Robichaud A, Tattersall FD, Choudhury I, Rodger IW.

Neuropharmacology. 1999 Feb;38(2):289-97.

PMID:
10218871
8.

A novel phosphodiesterase type 4 inhibitor, YM976 (4-(3-chlorophenyl)-1,7-diethylpyrido[2,3-d]pyrimidin-2(1H)-one), with little emetogenic activity.

Aoki M, Kobayashi M, Ishikawa J, Saita Y, Terai Y, Takayama K, Miyata K, Yamada T.

J Pharmacol Exp Ther. 2000 Oct;295(1):255-60.

9.

Studies on mechanisms of low emetogenicity of YM976, a novel phosphodiesterase type 4 inhibitor.

Aoki M, Fukunaga M, Sugimoto T, Hirano Y, Kobayashi M, Honda K, Yamada T.

J Pharmacol Exp Ther. 2001 Sep;298(3):1142-9.

10.

Proposal for pharmacologically distinct conformers of PDE4 cyclic AMP phosphodiesterases.

Souness JE, Rao S.

Cell Signal. 1997 May-Jun;9(3-4):227-36. Review.

PMID:
9218122
11.

Interaction between the antidepressant-like behavioral effects of beta adrenergic agonists and the cyclic AMP PDE inhibitor rolipram in rats.

Zhang HT, Huang Y, Mishler K, Roerig SC, O'Donnell JM.

Psychopharmacology (Berl). 2005 Oct;182(1):104-15. Epub 2005 Sep 29.

PMID:
16010541
12.

Phosphodiesterases do not limit beta1-adrenoceptor-mediated sinoatrial tachycardia: evidence with PDE3 and PDE4 in rabbits and PDE1-5 in rats.

Kaumann AJ, Galindo-Tovar A, Escudero E, Vargas ML.

Naunyn Schmiedebergs Arch Pharmacol. 2009 Nov;380(5):421-30. doi: 10.1007/s00210-009-0445-5. Epub 2009 Aug 20.

PMID:
19693491
13.

Central alpha-adrenoceptor subtypes involved in the emetic pathway in cats.

Hikasa Y, Akiba T, Iino Y, Matsukura M, Takase K, Ogasawara S.

Eur J Pharmacol. 1992 Dec 15;229(2-3):241-51.

PMID:
1362706
14.

Improvement of therapeutic index of phosphodiesterase type IV inhibitors as anti-Asthmatics.

Kim E, Chun HO, Jung SH, Kim JH, Lee JM, Suh BC, Xiang MX, Rhee CK.

Bioorg Med Chem Lett. 2003 Jul 21;13(14):2355-8.

PMID:
12824033
15.

Discriminative stimulus effects of the type-4 phosphodiesterase inhibitor rolipram in rats.

Makhay MM, Houslay MD, O'Donnell JM.

Psychopharmacology (Berl). 2001 Nov;158(3):297-304.

PMID:
11713620
16.

Substituted furans as inhibitors of the PDE4 enzyme.

Perrier H, Bayly C, Laliberté F, Huang Z, Rasori R, Robichaud A, Girard Y, Macdonald D.

Bioorg Med Chem Lett. 1999 Feb 8;9(3):323-6.

PMID:
10091677
17.

Pharmacology of N-(3,5-dichloro-1-oxido-4-pyridinyl)-8-methoxy-2-(trifluoromethyl)-5-quinoline carboxamide (SCH 351591), a novel, orally active phosphodiesterase 4 inhibitor.

Billah MM, Cooper N, Minnicozzi M, Warneck J, Wang P, Hey JA, Kreutner W, Rizzo CA, Smith SR, Young S, Chapman RW, Dyke H, Shih NY, Piwinski JJ, Cuss FM, Montana J, Ganguly AK, Egan RW.

J Pharmacol Exp Ther. 2002 Jul;302(1):127-37.

18.

7-Methoxybenzofuran-4-carboxamides as PDE 4 inhibitors: a potential treatment for asthma.

Buckley G, Cooper N, Dyke HJ, Galleway F, Gowers L, Gregory JC, Hannah DR, Haughan AF, Hellewell PG, Kendall HJ, Lowe C, Maxey R, Montana JG, Naylor R, Picken CL, Runcie KA, Sabin V, Tuladhar BR, Warneck JB.

Bioorg Med Chem Lett. 2000 Sep 18;10(18):2137-40.

PMID:
10999488
19.

Synthesis, structure-activity relationships, and pharmacological profile of 9-amino-4-oxo-1-phenyl-3,4,6,7-tetrahydro[1,4]diazepino[6, 7,1-hi]indoles: discovery of potent, selective phosphodiesterase type 4 inhibitors.

Burnouf C, Auclair E, Avenel N, Bertin B, Bigot C, Calvet A, Chan K, Durand C, Fasquelle V, Féru F, Gilbertsen R, Jacobelli H, Kebsi A, Lallier E, Maignel J, Martin B, Milano S, Ouagued M, Pascal Y, Pruniaux MP, Puaud J, Rocher MN, Terrasse C, Wrigglesworth R, Doherty AM.

J Med Chem. 2000 Dec 14;43(25):4850-67.

PMID:
11123995
20.

ASP3258, an orally active potent phosphodiesterase 4 inhibitor with low emetic activity.

Kobayashi M, Kubo S, Iwata M, Ohtsu Y, Takahashi K, Shimizu Y.

Int Immunopharmacol. 2011 Jun;11(6):732-9. doi: 10.1016/j.intimp.2011.01.023. Epub 2011 Feb 23.

PMID:
21315169

Supplemental Content

Support Center